<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205035</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4875s</org_study_id>
    <nct_id>NCT01205035</nct_id>
  </id_info>
  <brief_title>High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia</brief_title>
  <acronym>HD-LIPT</acronym>
  <official_title>High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia [HD-LIPT]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye Center of Northern Colorado, P.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eye Center of Northern Colorado, P.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic Parafoveal Telangiectasia (IPT) [also known as Idiopathic Perifoveal
      Telangiectasia, Idiopathic Juxtafoveal Telangiectasia (IJT, JFT) and Macular Telangiectasia
      (MacTel)] is a disorder of unknown etiology. IPT is classified as Group 2A in the Gass
      classification of macular telangiectasias (Reference 1,5) - a bilateral, but not always
      symmetric disorder. It is characterized in its early stages by dilation and loss of
      parafoveal capillaries accompanied by angiographic leakage, &quot;right angle&quot; venules, central
      and parafoveal intraretinal cysts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESCRIPTION OF THE STUDY

      This is an open-label, Phase I/II study of intravitreally administered ranibizumab in
      subjects with nonproliferative Idiopathic Parafoveal Telangiectasia (IPT).

      Consented, enrolled subjects will be randomized into two groups: observation and treatment.
      The observation group will be monitored monthly while the treatment group will receive three
      open-label intravitreal injections of 1.0 mg ranibizumab administered every 30 days for 3
      months and then as needed monthly, based on defined criteria. NOTE: The original protocol had
      the treatment group dosed at 2.0 mg/0.05mL. However, the 2.0mg dose will become unavailable
      beginning January 31, 2012. Therefore, the protocol amendment submitted in December 2011
      changed the 2.0mg arm to a 1.0mg/ 0.10mL arm. Please note that three patients were already
      treated with 2.0mg before the amendment was submitted, so they will be switched to 1.0mg if
      they have not completed the study when the 2.0 dose is no longer available in January 2012.

      Protocol: FVF4875s Final 6/P

      29MAR2010

      3.2

      RATIONALE FOR STUDY DESIGN

      As IPT is a chronically progressive condition, the purpose of this study is to see if
      high-dose ranibizumab can slow or stop the leakage and growth of existing, dilated, macular
      vessels in cases where no co-existing neovascularization exists as defined by fluorescein
      angiography and Ocular Coherence Tomography (OCT). Other outcomes include stabilization of
      visual acuity compared to observation group (defined by best corrected Early Treatment
      Diabetic Retinopathy Study (ETDRS) measurements), and changes in ultrastructural features, as
      defined by OCT,

      3.3

      OUTCOME MEASURES

      3.3.1 Primary Outcome Measures

      To compare the change in visual acuity from baseline to one year in patients with
      nonproliferative IPT who are either treated with high-dose (1.0mg) ranibizumab or observed.

      3.3.2 Secondary Outcome Measures

      i. To compare the change in visual acuity from baseline to 6 months and 9 months in patients
      with nonproliferative IPT who are either treated with high- dose (1.0mg) ranibizumab or
      observed.

      ii. To assess OCT changes in standard Central Subfield Thickness (CST) from baseline to 6
      months, 9 months and 12 months.

      iii. To assess safety of administering 1.0mg ranibizumab (Lucentis) in patients with
      nonproliferative IPT at 6 months, 9 months and 12 months.

      iv. To assess changes in angiographic leakage from baseline at 6 and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity Change From Baseline to Month 12 of the Study</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity From Baseline to Month 6 and From Baseline to 9 Months</measure>
    <time_frame>Baseline to 6 months and baseline to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Standard Central Subfield Thickness (CST) as Measured by OCT From Baseline to 6, 9, and 12 Months</measure>
    <time_frame>Baseline to 6, 9, and 12 months</time_frame>
    <description>A large decrease in CST thickness may be indicative of a worse clinical outcome. These measurements are done to ensure safety of the participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events Associated to the Administration of Ranibizumab 2.0mg</measure>
    <time_frame>Baseline to 6 month, baseline to 9 month and baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Leakage From Baseline to Month 6 and 12</measure>
    <time_frame>Baseline to 6 and baseline to 12 months</time_frame>
    <description>Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 6. Also any decreases of angiographic leakage was counted between baseline and 6 month. The same was done between baseline and 12 month.
Any increase of angiographic leakage was counted as a +1. Likewise, any decrease of angiographic leakage was counted as a -1. The sum was calculated based on the number of participants in each arm and the total shown in the outcome. For example: if across the three injected participants for their 6 month visit, two of them showed an increase of angiographic leakage and one showed a decrease, then the outcome would be, (+1) + (+1) + (-1)= +1. Likewise, if the same three participant's 12 month visit showed two with a decrease in leakage and one with no changes in leakage, the outcome would be, (-1) + (-1) + (0)= -2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Retinal Diseases</condition>
  <condition>Telangiectasis</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation; No treatment given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal ranibizumab 2.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab 2.0mg</intervention_name>
    <description>Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
    <arm_group_label>Intravitreal ranibizumab 2.0mg</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt; 18 years

          -  Presence of nonproliferative IPT confirmed by fluorescein angiography and
             spectral-domain OCT

          -  Age greater than 18

          -  Vision equal to or worse than 20/25 and better than or equal to 20/400 by ETDRS chart,
             without co-existing choroidal neovascularization.

          -  Physical ability and reasonable expectation to maintain all follow-up appointments.

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) or lactation

          -  Premenopausal women not using adequate contraception. The following are considered
             effective means of contraception: surgical sterilization or use of oral
             contraceptives, barrier contraception with either a condom or diaphragm in conjunction
             with spermicidal gel, an IUD, or contraceptive hormone implant or patch.

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous ophthalmologic investigation or trial

          -  Any patient with proliferative diabetic retinopathy, diabetic macular edema, uveitis,
             history of ocular trauma, severe glaucoma, neovascular age-related macular
             degeneration

          -  Duration of previous treatment of IPT that exceeds two years.

          -  Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic
             retinopathy) that, in the opinion of the investigator, could either:

          -  Require medical or surgical intervention during the 12-month study period to prevent
             or treat visual loss that might result from that condition, or

          -  If allowed to progress untreated, could likely contribute to loss of at least 2
             Snellen equivalent lines of Best Corrected Visual Acuity (BCVA) over the study period

          -  Prior/Concomitant Treatment:

          -  Previous steroids (oral) within 30 days preceding Day 0

          -  Previous participation in any studies of investigational drugs within 30 days
             preceding Day 0 (excluding vitamins and minerals)

          -  Prior participation in a Genentech ranibizumab clinical trial within 60 days.

          -  History of receiving intravitreal injections of ranibizumab, bevacizumab, pegaptanib,
             or any other intravitreal medication within 60 days of first injection. History of
             receiving intravitreal or subtenons triamcinolone within 90 days of first injection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Korotkin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Center of Northern Colorado</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Center of Northern Colorado</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <results_first_submitted>March 18, 2015</results_first_submitted>
  <results_first_submitted_qc>March 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2015</results_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eye Center of Northern Colorado, P.C.</investigator_affiliation>
    <investigator_full_name>Arthur Korotkin, M.D.</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Idiopathic Parafoveal Telangiectasia</keyword>
  <keyword>Macular Telangiectasia</keyword>
  <keyword>Macula Lutea/pathology</keyword>
  <keyword>Retinal Diseases/pathology</keyword>
  <keyword>Retinal Pigments/metabolism</keyword>
  <keyword>Telangiectasis/metabolism</keyword>
  <keyword>Telangiectasis/pathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Observation</title>
          <description>Observation; No treatment given</description>
        </group>
        <group group_id="P2">
          <title>Intravitreal Ranibizumab 2.0mg</title>
          <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Observation</title>
          <description>Observation; No treatment given</description>
        </group>
        <group group_id="B2">
          <title>Intravitreal Ranibizumab 2.0mg</title>
          <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="52" upper_limit="76"/>
                    <measurement group_id="B2" value="65" lower_limit="52" upper_limit="76"/>
                    <measurement group_id="B3" value="66.5" lower_limit="52" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity Change From Baseline to Month 12 of the Study</title>
        <time_frame>Baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observation</title>
            <description>Observation; No treatment given</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 2.0mg</title>
            <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity Change From Baseline to Month 12 of the Study</title>
          <units>LogMAR Unit</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.12" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity From Baseline to Month 6 and From Baseline to 9 Months</title>
        <time_frame>Baseline to 6 months and baseline to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observation</title>
            <description>Observation; No treatment given</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 2.0mg</title>
            <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity From Baseline to Month 6 and From Baseline to 9 Months</title>
          <units>LogMAR Unit</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.04" upper_limit="0.04"/>
                    <measurement group_id="O2" value="-0.10" lower_limit="-0.2" upper_limit="-0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 9 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="0.02" upper_limit="0.02"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-0.14" upper_limit="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Standard Central Subfield Thickness (CST) as Measured by OCT From Baseline to 6, 9, and 12 Months</title>
        <description>A large decrease in CST thickness may be indicative of a worse clinical outcome. These measurements are done to ensure safety of the participants.</description>
        <time_frame>Baseline to 6, 9, and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observation</title>
            <description>Observation; No treatment given</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 2.0mg</title>
            <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Standard Central Subfield Thickness (CST) as Measured by OCT From Baseline to 6, 9, and 12 Months</title>
          <description>A large decrease in CST thickness may be indicative of a worse clinical outcome. These measurements are done to ensure safety of the participants.</description>
          <units>Micrometer</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20" lower_limit="-20" upper_limit="-20"/>
                    <measurement group_id="O2" value="7" lower_limit="-2" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 9 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16" lower_limit="-16" upper_limit="-16"/>
                    <measurement group_id="O2" value="-6" lower_limit="-17" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" lower_limit="-11" upper_limit="-11"/>
                    <measurement group_id="O2" value="-4" lower_limit="-14" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events Associated to the Administration of Ranibizumab 2.0mg</title>
        <time_frame>Baseline to 6 month, baseline to 9 month and baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observation</title>
            <description>Observation; No treatment given</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 2.0mg</title>
            <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events Associated to the Administration of Ranibizumab 2.0mg</title>
          <units>Number of Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 9 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Leakage From Baseline to Month 6 and 12</title>
        <description>Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 6. Also any decreases of angiographic leakage was counted between baseline and 6 month. The same was done between baseline and 12 month.
Any increase of angiographic leakage was counted as a +1. Likewise, any decrease of angiographic leakage was counted as a -1. The sum was calculated based on the number of participants in each arm and the total shown in the outcome. For example: if across the three injected participants for their 6 month visit, two of them showed an increase of angiographic leakage and one showed a decrease, then the outcome would be, (+1) + (+1) + (-1)= +1. Likewise, if the same three participant's 12 month visit showed two with a decrease in leakage and one with no changes in leakage, the outcome would be, (-1) + (-1) + (0)= -2</description>
        <time_frame>Baseline to 6 and baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observation</title>
            <description>Observation; No treatment given</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 2.0mg</title>
            <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Leakage From Baseline to Month 6 and 12</title>
          <description>Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 6. Also any decreases of angiographic leakage was counted between baseline and 6 month. The same was done between baseline and 12 month.
Any increase of angiographic leakage was counted as a +1. Likewise, any decrease of angiographic leakage was counted as a -1. The sum was calculated based on the number of participants in each arm and the total shown in the outcome. For example: if across the three injected participants for their 6 month visit, two of them showed an increase of angiographic leakage and one showed a decrease, then the outcome would be, (+1) + (+1) + (-1)= +1. Likewise, if the same three participant's 12 month visit showed two with a decrease in leakage and one with no changes in leakage, the outcome would be, (-1) + (-1) + (0)= -2</description>
          <units>Sum of increases (+1) and decreases (-1)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="-2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Observation</title>
          <description>Observation; No treatment given</description>
        </group>
        <group group_id="E2">
          <title>Intravitreal Ranibizumab 2.0mg</title>
          <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Blood Pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stiff Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Arthur Korotkin, MD</name_or_title>
      <organization>Eye Center of Northern Colorado, PC</organization>
      <phone>970-221-2222</phone>
      <email>retina@eyecenternoco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

